Eton Patent-Cliff Exposure & CMS Drug Spending Portfolio

Eton (US): 5 reconciled FDA prescription therapies (45.1% 2025 to 2030 cliff risk), $15.9M 2024 CMS Part D & Medicaid spend, and 23 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure45.1%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$15.9M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$15.9M
California HCAI SB 17 Filings23 WAC filings (max 1555.1% 2-yr change)